Proglucagon peptide secretion profiles in type 2 diabetes before and after bariatric surgery: 1-year prospective study
Open Access
- 1 January 2020
- journal article
- research article
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 8 (1), e001076
- https://doi.org/10.1136/bmjdrc-2019-001076
Abstract
IntroductionHyperglucagonemia is a key pathophysiological driver of type 2 diabetes. Although Roux-en-Y gastric bypass (RYGB) is a highly effective treatment for diabetes, it is presently unclear how surgery alters glucagon physiology. The aim of this study was to characterize the behavior of proglucagon-derived peptide (glucagon, glucagon-like peptide-1 (GLP-1), oxyntomodulin, glicentin) secretion after RYGB surgery.Research design and methodsProspective study of 19 patients with obesity and pre-diabetes/diabetes undergoing RYGB. We assessed the glucose, insulin, GLP-1, glucose-dependent insulinotropic peptide (GIP), oxyntomodulin, glicentin and glucagon responses to a mixed-meal test (MMT) before and 1, 3 and 12 months after surgery. Glucagon was measured using a Mercodia glucagon ELISA using the 'Alternative' improved specificity protocol, which was validated against a reference liquid chromatography combined with mass spectrometry method.ResultsAfter RYGB, there were early improvements in fasting glucose and glucose tolerance and the insulin response to MMT was accelerated and amplified, in parallel to significant increases in postprandial GLP-1, oxyntomodulin and glicentin secretion. There was a significant decrease in fasting glucagon levels at the later time points of 3 and 12 months after surgery. Glucagon was secreted in response to the MMT preoperatively and postoperatively in all patients and there was no significant change in this postprandial secretion. There was no significant change in GIP secretion.ConclusionsThere is a clear difference in the dynamics of secretion of proglucagon peptides after RYGB. The reduction in fasting glucagon secretion may be one of the mechanisms driving later improvements in glycemia after RYGB.Trial registration numberNCT01945840.Keywords
Funding Information
- National Institute for Health Research (Imperial Biomedical Research Centre Funding)
- UK Medical Research Council (Experimental Challenge Grant (MR/K02115X/1))
- Efficacy and Mechanism Evaluation Programme (13/121/07)
This publication has 43 references indexed in Scilit:
- Unraveling oxyntomodulin, GLP1's enigmatic brotherJournal of Endocrinology, 2012
- Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose toleranceAmerican Journal of Physiology-Endocrinology and Metabolism, 2012
- Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeoverJCI Insight, 2012
- Gastric Bypass Surgery Enhances Glucagon-Like Peptide 1–Stimulated Postprandial Insulin Secretion in HumansDiabetes, 2011
- Effect of Weight Loss by Gastric Bypass Surgery Versus Hypocaloric Diet on Glucose and Incretin Levels in Patients with Type 2 DiabetesJournal of Clinical Endocrinology & Metabolism, 2008
- Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric bandingSurgery for Obesity and Related Diseases, 2007
- Gut Hormones as Mediators of Appetite and Weight Loss After Roux-en-Y Gastric BypassAnnals of Surgery, 2007
- Gut Hormone Profiles Following Bariatric Surgery Favor an Anorectic State, Facilitate Weight Loss, and Improve Metabolic ParametersAnnals of Surgery, 2006
- Oxyntomodulin and glicentin are potent inhibitors of the fed motility pattern in small intestineNeurogastroenterology & Motility, 2004
- ENTEROGLUCAGONAnnual Review of Physiology, 1997